Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 31 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Kakafika, Anna I  [Clear All Filters]
2010
Karagiannis, A., Tziomalos K., Mikhailidis D. P., Semertzidis P., Kountana E., Kakafika A. I., et al. (2010).  Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients.. Neurol Res. 32(3), 326-31.
2009
Anagnostis, P., Karagiannis A., Tziomalos K., Kakafika A. I., Athyros V. G., & Mikhailidis D. P. (2009).  Adrenal incidentaloma: a diagnostic challenge.. Hormones (Athens). 8(3), 163-84.
Pagourelias, E. D., Koumaras C., Kakafika A. I., Tziomalos K., Zorou P. G., Athyros V. G., et al. (2009).  Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. Angiology. 60(1), 74-81.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Tziomalos, K., Kakafika A. I., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  The role of statins for the primary and secondary prevention of coronary heart disease in women.. Curr Pharm Des. 15(10), 1054-62.
2008
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Athyros, V. G., Kakafika A. I., Karagiannis A., & Mikhailidis D. P. (2008).  Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis. 200(1), 1-12.
Athyros, V. G., Tziomalos K., Kakafika A. I., Koumaras H., Karagiannis A., & Mikhailidis D. P. (2008).  Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.. Am J Cardiol. 101(4), 483-5.
Athyros, V. G., Kakafika A. I., Karagiannis A., Koragiannis A., Mikhailidis D. P., & Mikhalidis D. P. (2008).  Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.. Am J Cardiol. 101(11), 1679-80.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Karagiannis, A., Mikhailidis D. P., Tziomalos K., Kakafika A. I., & Athyros V. G. (2008).  Has the time come for a new definition of microalbuminuria?. Curr Vasc Pharmacol. 6(2), 81-3.
Karagiannis, A., Tziomalos K., Kakafika A. I., Athyros V. G., Harsoulis F., & Mikhailidis D. P. (2008).  Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.. Endocr Relat Cancer. 15(3), 693-700.
Kakafika, A. I., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother. 9(9), 1437-40.
Karagiannis, A., Tziomalos K., Papageorgiou A., Kakafika A. I., Pagourelias E. D., Anagnostis P., et al. (2008).  Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.. Expert Opin Pharmacother. 9(4), 509-15.
Athyros, V. G., Kakafika A. I., Tziomalos K., Papageorgiou A. A., & Karagiannis A. (2008).  Statins for the prevention of first or recurrent stroke.. Curr Vasc Pharmacol. 6(2), 124-33.
2007
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Karagiannis A. (2007).  Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother. 8(5), 529-35.
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Karagiannis, A., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Athyros V. G. (2007).  Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. Curr Pharm Des. 13(2), 229-39.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Mikhailidis D. P., Pagourelias E. D., Kakafika A. I., Skaperdas A., et al. (2007).  Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother. 8(14), 2267-77.
Athyros, V. G., Mikhailidis D. P., Liberopoulos E. N., Kakafika A. I., Karagiannis A., Papageorgiou A. A., et al. (2007).  Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.. Nephrol Dial Transplant. 22(1), 118-27.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Karagiannis A., Hatzitolios A., Tziomalos K., et al. (2007).  Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.. Curr Drug Targets. 8(3), 483-8.
Kakafika, A. I., Mikhailidis D. P., Wierzbicki A. S., Karagiannis A., & Athyros V. G. (2007).  PCI and stable coronary heart disease--COURAGE to change our minds?. Curr Vasc Pharmacol. 5(3), 173-4.
Kakafika, A. I., Mikhailidis D. P., Karagiannis A., & Athyros V. G. (2007).  The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.. J Clin Pharmacol. 47(5), 642-52.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές